JP2023513794A5 - - Google Patents

Info

Publication number
JP2023513794A5
JP2023513794A5 JP2022549145A JP2022549145A JP2023513794A5 JP 2023513794 A5 JP2023513794 A5 JP 2023513794A5 JP 2022549145 A JP2022549145 A JP 2022549145A JP 2022549145 A JP2022549145 A JP 2022549145A JP 2023513794 A5 JP2023513794 A5 JP 2023513794A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
alkyl
cycloalkyl
heterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022549145A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023513794A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/018040 external-priority patent/WO2021163629A1/en
Publication of JP2023513794A publication Critical patent/JP2023513794A/ja
Publication of JP2023513794A5 publication Critical patent/JP2023513794A5/ja
Pending legal-status Critical Current

Links

JP2022549145A 2020-02-14 2021-02-12 Ｕｌｋ１／２の阻害剤およびその使用方法 Pending JP2023513794A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062977040P 2020-02-14 2020-02-14
US62/977,040 2020-02-14
PCT/US2021/018040 WO2021163629A1 (en) 2020-02-14 2021-02-12 Inhibitors of ulk1/2 and methods of using same

Publications (2)

Publication Number Publication Date
JP2023513794A JP2023513794A (ja) 2023-04-03
JP2023513794A5 true JP2023513794A5 (https=) 2024-02-20

Family

ID=77292760

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022549145A Pending JP2023513794A (ja) 2020-02-14 2021-02-12 Ｕｌｋ１／２の阻害剤およびその使用方法

Country Status (8)

Country Link
US (1) US20230135635A1 (https=)
EP (1) EP4103182A4 (https=)
JP (1) JP2023513794A (https=)
KR (1) KR20220153581A (https=)
CN (1) CN115515589A (https=)
AU (1) AU2021218739A1 (https=)
CA (1) CA3171187A1 (https=)
WO (1) WO2021163629A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220153582A (ko) 2020-02-14 2022-11-18 솔크 인스티튜트 포 바이올로지칼 스터디즈 마크로시클릭 ulk1/2 억제제
WO2022072668A1 (en) * 2020-09-30 2022-04-07 Salk Institute For Biological Studies Patient selection biomarkers for treatment with ulk inhibitors
EP4464699A1 (en) * 2022-01-14 2024-11-20 Lisen Therapeutics, Inc. Pyrimidine-2,4-diamine derivatives as well as preparation method therefor and use thereof
WO2024140401A1 (zh) * 2022-12-30 2024-07-04 捷思英达控股有限公司 作为激酶抑制剂的杂环化合物以及包括其的组合物
CN116768885B (zh) * 2023-03-14 2026-03-24 浙江大学 N2-取代双环-2-氨基嘧啶类衍生物、其制备方法及医药用途
WO2024233766A1 (en) * 2023-05-10 2024-11-14 Erasca, Inc. Macrocyclic ulk1/2 inhibitors and their use thereof
WO2025045182A1 (zh) * 2023-09-01 2025-03-06 深圳众格生物科技有限公司 Ulk1抑制剂及其制备方法和用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6939874B2 (en) * 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
WO2006129100A1 (en) * 2005-06-03 2006-12-07 Glaxo Group Limited Novel compounds
WO2007028445A1 (en) * 2005-07-15 2007-03-15 Glaxo Group Limited 6-indolyl-4-yl-amino-5-halogeno-2-pyrimidinyl-amino derivatives
JP5161233B2 (ja) * 2006-10-19 2013-03-13 ライジェル ファーマシューティカルズ， インコーポレイテッド 自己免疫疾患の処置のためのｊａｋキナーゼの阻害剤としての２，４−ピリミジンアミン誘導体
JP2010523639A (ja) * 2007-04-12 2010-07-15 エフ．ホフマン−ラ ロシュ アーゲー 医薬化合物
CN101903357A (zh) * 2007-07-17 2010-12-01 里格尔药品股份有限公司 作为pkc抑制剂的环状胺取代的嘧啶二胺
AU2009262198B2 (en) * 2008-06-25 2012-09-27 Irm Llc Pyrimidine derivatives as kinase inhibitors
EP3473299A1 (en) * 2013-06-05 2019-04-24 Salk Institute for Biological Studies Vitamin d receptor agonists to treat diseases involving cxcl12 activity
US10300058B2 (en) * 2014-04-18 2019-05-28 Xuanzhu Pharma Co., Ltd. Tyrosine kinase inhibitor and uses thereof
EP3159338A4 (en) * 2014-06-17 2018-01-24 Korea Research Institute of Chemical Technology Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient
US10266549B2 (en) * 2014-08-25 2019-04-23 Salk Institute For Biological Studies ULK1 inhibitors and methods using same
KR102608590B1 (ko) * 2014-09-24 2023-12-01 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양 살상 바이러스 및 이의 사용방법
CN105524045B (zh) * 2014-10-22 2020-04-10 山东轩竹医药科技有限公司 四环类间变性淋巴瘤激酶抑制剂
US20160159774A1 (en) * 2014-12-05 2016-06-09 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
CN106188029B (zh) * 2015-05-05 2018-09-18 山东轩竹医药科技有限公司 二并环类间变性淋巴瘤激酶抑制剂
AU2017346845B2 (en) * 2016-10-18 2021-12-02 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating DCLK1/2-mediated disorders
WO2018102366A1 (en) * 2016-11-30 2018-06-07 Ariad Pharmaceuticals, Inc. Anilinopyrimidines as haematopoietic progenitor kinase 1 (hpk1) inhibitors
CN110831937A (zh) * 2017-05-02 2020-02-21 韩国化学研究院 嘧啶衍生物化合物、其光学异构体或其药学上可接受的盐及包含其为有效成分的Tyro3相关疾病的预防或治疗用组合物

Similar Documents

Publication Publication Date Title
JP2023513794A5 (https=)
JP6553551B2 (ja) Ｂ型肝炎抗ウイルス剤
CN1826313B (zh) 选择性雄激素受体调节剂的大规模合成
JP2009518296A5 (https=)
JP2009504803A5 (https=)
JP2020503009A5 (https=)
JP2010519289A5 (https=)
JP2022537521A5 (https=)
JP2006515585A5 (https=)
JP2025509438A5 (https=)
AU2018209175B2 (en) Therapeutic inhibitors of the reverse mode of ATP synthase
JP2008517923A5 (https=)
JP2005526024A5 (https=)
JP2007532627A5 (https=)
JP2023538524A5 (https=)
JP2005515976A5 (https=)
ES2488821T3 (es) Proceso de preparación de un compuesto antiviral
JP2005516898A5 (https=)
JP2005504795A5 (https=)
JP2007536262A5 (https=)
TW200813066A (en) Novel compounds
JPWO2003018010A1 (ja) 動脈硬化作用に基づく疾患の予防及び／または治療薬
JP2008520673A (ja) Ｈｃｖ阻害剤
JP2023518208A5 (https=)
CN111777638A (zh) 喹啉类化合物、其制备方法、药物组合物和用途